Endocrine Abstracts

Introduction: Currently, type 1 diabetes (T1D) is defined by the autoimmune destruction of the pancreatic β cells that culminates in dependence on exogenous insulin, typically 1–3 years after diagnosis. This ability to maintain a residual function of pancreatic β cells is, however, heterogeneous, appearing to be worst if the disease is early diagnosed. Recently, it was demonstrated that many type 1 diabetic patients produce small amounts of insulin decades after...

Pituitary carcinomas are rare and represent a challenge in clinical practice. Most secondary tumour localizations are intracranial and spinal, followed by liver, cervical lymph node, bone and, rarely, lung. PC frequently exhibit resistance to most usual therapies and the mean survival time is usually <4 years once metastases have been identified. Ectopic ACTH Syndrome is, in up to 50% cases, caused by lung tumours including carcinoids or Small Cell Lung Carcinomas (SCLC). ...

Primary Aldosteronism (PA) is the most prevalent cause of secondary hypertension. The aim of this work was to characterize the diagnostic workup, treatment and follow-up of confirmed PA.The adrenal tumour study group of the Portuguese Society of Endocrinology undertook the first retrospective multicentre study of Portuguese PA patients. Data was gathered from nine Portuguese Endocrinology centres (three in the north, one in the centre and five in the sou...

Background: Residual C-peptide (CP) secretion has been associated with better glycemic control in patients with type 1 diabetes (T1D).Aim: To evaluate how residual fasting CP (fCP) secretion impacts glycemic control in T1D and to identify possible confounding factors.Methods: A retrospective analysis of adult patients with T1D followed in our department that had their fCP and glucose levels obtained on the same blood sample during ...

Background: The use of Flash Glucose Monitoring (FGM) for the management of type 1 diabetes mellitus (T1D) is rapidly increasing.Aims: To assess the longitudinal evolution of glycated haemoglobin (HbA1c) and body mass index (BMI) with the use of FGM in patients with T1D; to determine predictive factors of benefit with the use of this technology.Materials and methods: Retrospective study of T1D patients, using FGM ≥6 months an...